Tradewinds Capital Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $67.8K | Hold |
1,393
| – | – | 0.02% | 171 |
|
|
2025
Q1 | $47.4K | Buy |
1,393
+183
| +15% | +$6.23K | 0.01% | 196 |
|
|
2024
Q4 | $47.6K | Buy |
1,210
+100
| +9% | +$3.94K | 0.01% | 206 |
|
|
2024
Q3 | $52.1K | Hold |
1,110
| – | – | 0.01% | 185 |
|
|
2024
Q2 | $60K | Buy |
1,110
+400
| +56% | +$21.6K | 0.02% | 161 |
|
|
2024
Q1 | $48.4K | Hold |
710
| – | – | 0.01% | 166 |
|
|
2023
Q4 | $44.4K | Hold |
710
| – | – | 0.02% | 130 |
|
|
2023
Q3 | $32.2K | Buy |
710
+600
| +545% | +$27.2K | 0.01% | 153 |
|
|
2023
Q2 | $6.18K | Hold |
110
| – | – | ﹤0.01% | 261 |
|
|
2023
Q1 | $4.98K | Sell |
110
-5
| -4% | -$226 | ﹤0.01% | 283 |
|
|
2022
Q4 | $4.68K | Hold |
115
| – | – | ﹤0.01% | 292 |
|
|
2022
Q3 | $8K | Buy |
115
+5
| +5% | +$348 | ﹤0.01% | 218 |
|
|
2022
Q2 | $7K | Hold |
110
| – | – | ﹤0.01% | 235 |
|
|
2022
Q1 | $7K | Hold |
110
| – | – | ﹤0.01% | 517 |
|
|
2021
Q4 | $8K | Buy |
110
+50
| +83% | +$3.64K | ﹤0.01% | 520 |
|
|
2021
Q3 | $7K | Hold |
60
| – | – | ﹤0.01% | 508 |
|
|
2021
Q2 | $10K | Hold |
60
| – | – | ﹤0.01% | 473 |
|
|
2021
Q1 | $7K | Hold |
60
| – | – | ﹤0.01% | 496 |
|
|
2020
Q4 | $9K | Hold |
60
| – | – | ﹤0.01% | 433 |
|
|
2020
Q3 | $5K | Hold |
60
| – | – | ﹤0.01% | 478 |
|
|
2020
Q2 | $4K | Hold |
60
| – | – | ﹤0.01% | 492 |
|
|
2020
Q1 | $3K | Sell |
60
-15
| -20% | -$750 | ﹤0.01% | 497 |
|
|
2019
Q4 | $5K | Buy |
+75
| New | +$5K | ﹤0.01% | 496 |
|
|
2019
Q3 | – | Sell |
-65
| Closed | -$3K | – | 615 |
|
|
2019
Q2 | $3K | Sell |
65
-20
| -24% | -$923 | ﹤0.01% | 485 |
|
|
2019
Q1 | $3K | Buy |
+85
| New | +$3K | ﹤0.01% | 499 |
|